Skip to main content
Erschienen in: Clinical Rheumatology 9/2019

30.05.2019 | Original Article

Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset “sine psoriasis”

verfasst von: Francesco Caso, Loredana Postiglione, Bianca Covelli, Margherita Ricciardone, Gaetano Di Spigna, Pietro Formisano, Vittoria D’Esposito, Nicolò Girolimetto, Marco Tasso, Rosario Peluso, Luca Navarini, Massimo Ciccozzi, Domenico Paolo Emanuele Margiotta, Francesca Oliviero, Antonella Afeltra, Leonardo Punzi, Antonio Del Puente, Raffaele Scarpa, Luisa Costa

Erschienen in: Clinical Rheumatology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

Adipokines have been considered in the pathogenesis of the inflammatory processes of psoriatic arthritis (PsA). The main aim of the current study is to investigate possible differences and correlations between adipokines and clinical expression in PsA patients with and without clinical evident psoriasis.

Methods

Serum levels of TNF-α, IL-6, leptin, resistin, visfatin, and ghrelin were measured in 80 consecutive PsA patients, 42 PsA patients with clinically evident psoriasis (group 1) and 38 PsA patients sine psoriasis (group 2), fulfilling the CASPAR criteria.

Results

Patients of the two groups were not significantly different for levels of TNF-α, IL-6, leptin, resistin, visfatin, and ghrelin. In the entire cohort, a positive association has been shown between leptin levels and female gender (β = 0.3, p = 0.001), BMI (β = 0.8, p < 0.0001), tender joint count (β = 0.23, p = 0.05), and patient pain-VAS score (β = 0.4, p = 0.049). In group 1, serum concentration of leptin was associated with female gender (β = 0.41, p < 0.0001) and BMI (β = 0.6, p = 0.012), whereas in group 2, a positive association was shown between leptin levels and BMI (β = 0.7, p = 0.003) and CRP (β = 0.35, p = 0.012). With regard to resistin, in the multivariate model, only the association between resistin and IL-6 was found (β = 0.33, p = 0.002). The association between resistin and IL-6 was confirmed in group 1 (β = 0.46, p = 0.004) but not in group 2.

Conclusions

Until today, the present study represents the first investigating difference in the adipokine pattern between PsA patients with psoriasis and sine psoriasis. We report a strict interplay between leptin, female gender, BMI, and inflammatory activity in overall PsA patients. In PsA patients with clinical evident psoriasis, leptin was associated with female gender and BMI, and a close association between resistin and IL-6 was found. Further, a positive association between leptin levels and BMI and CRP was found in PsA sine psoriasis patients. Further studies are also advocated for clarifying the possible role of these adipokines as laboratory findings or as disease mediators in addressing the different phenotypes of the disease.
Key Points
Levels of TNF-α, IL-6, leptin, resistin, visfatin, and ghrelin did not differ between PsA patients with clinical evident psoriasis and PsA sine psoriasis.
There is a strict interplay between leptin, female gender, BMI, and inflammatory activity in PsA.
There is a close association between resistin and IL-6 in PsA patients with clinical evident psoriasis.
Literatur
1.
Zurück zum Zitat Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. Springerplus 3:759CrossRefPubMedPubMedCentral Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. Springerplus 3:759CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L (2016) Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol 35:1893–1901CrossRefPubMed Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L (2016) Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol 35:1893–1901CrossRefPubMed
3.
Zurück zum Zitat Lapadula G, Marchesoni A, Salaffi F, Ramonda R, Salvarani C, Punzi L, Costa L, Caso F, Simone D, Baiocchi G, Scioscia C, Di Carlo M, Scarpa R, Ferraccioli G (2016) Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA). Reumatismo 68:126–136CrossRefPubMed Lapadula G, Marchesoni A, Salaffi F, Ramonda R, Salvarani C, Punzi L, Costa L, Caso F, Simone D, Baiocchi G, Scioscia C, Di Carlo M, Scarpa R, Ferraccioli G (2016) Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA). Reumatismo 68:126–136CrossRefPubMed
4.
Zurück zum Zitat Olivieri I, Padula A, D’Angelo S, Cutro MS (2009) Psoriatic arthritis sine psoriasis. J Rheumatol Suppl 83:28–29CrossRefPubMed Olivieri I, Padula A, D’Angelo S, Cutro MS (2009) Psoriatic arthritis sine psoriasis. J Rheumatol Suppl 83:28–29CrossRefPubMed
5.
Zurück zum Zitat Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMed Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMed
6.
Zurück zum Zitat Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N (2012) The ClASsification for Psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39:154–156CrossRefPubMed Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N (2012) The ClASsification for Psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39:154–156CrossRefPubMed
7.
Zurück zum Zitat Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301CrossRefPubMed Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301CrossRefPubMed
8.
Zurück zum Zitat Costa L, Caso F, D’Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–715CrossRefPubMed Costa L, Caso F, D’Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–715CrossRefPubMed
9.
Zurück zum Zitat Peluso R, Caso F, Tasso M, Ambrosino P, Dario Di Minno MN, Lupoli R, Criscuolo L, Caso P, Ursini F, Puente AD, Scarpa R, Costa L, On Behalf Of CaRRDs Study Group (2018) Cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients. Rev Recent Clin Trials 13:199–209CrossRefPubMedPubMedCentral Peluso R, Caso F, Tasso M, Ambrosino P, Dario Di Minno MN, Lupoli R, Criscuolo L, Caso P, Ursini F, Puente AD, Scarpa R, Costa L, On Behalf Of CaRRDs Study Group (2018) Cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients. Rev Recent Clin Trials 13:199–209CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33:833–839PubMed Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33:833–839PubMed
11.
Zurück zum Zitat Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–153CrossRefPubMed Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–153CrossRefPubMed
13.
Zurück zum Zitat Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375:181–183CrossRefPubMed Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375:181–183CrossRefPubMed
14.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 85:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 85:2486–2497CrossRef
15.
16.
Zurück zum Zitat Hutcheson J (2015) Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75:272–279CrossRefPubMed Hutcheson J (2015) Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75:272–279CrossRefPubMed
17.
Zurück zum Zitat Gentile M, Peluso R, Di Minno MND, Costa L, Caso F, de Simone B, Iannuzzo G, Scarpa R, Rubba P (2016) Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clin Rheumatol 35:2023–2029CrossRefPubMed Gentile M, Peluso R, Di Minno MND, Costa L, Caso F, de Simone B, Iannuzzo G, Scarpa R, Rubba P (2016) Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clin Rheumatol 35:2023–2029CrossRefPubMed
18.
Zurück zum Zitat Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. Rheumatology (Oxford) 47:718–723CrossRef Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. Rheumatology (Oxford) 47:718–723CrossRef
19.
Zurück zum Zitat Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12:315–331CrossRefPubMed Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12:315–331CrossRefPubMed
20.
Zurück zum Zitat Sethi JK, Hotamisligil GS (1999) The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19–29CrossRefPubMed Sethi JK, Hotamisligil GS (1999) The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19–29CrossRefPubMed
21.
Zurück zum Zitat Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355CrossRefPubMed Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355CrossRefPubMed
22.
Zurück zum Zitat Gremese E, Ferraccioli G (2011) The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 10:582–589CrossRefPubMed Gremese E, Ferraccioli G (2011) The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 10:582–589CrossRefPubMed
23.
Zurück zum Zitat Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH (2007) Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75:235–240CrossRefPubMed Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH (2007) Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75:235–240CrossRefPubMed
24.
Zurück zum Zitat Fonseca JE, Santos MJ, Canha˜o H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538–542CrossRefPubMed Fonseca JE, Santos MJ, Canha˜o H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538–542CrossRefPubMed
25.
Zurück zum Zitat Caso F, Costa L, Nucera V, Barilaro G, Masala IF, Talotta R, Caso P, Scarpa R, Sarzi-Puttini P, Atzeni F (2018) From autoinflammation to autoimmunity: old and recent findings. Clin Rheumatol 37:2305–2321CrossRefPubMed Caso F, Costa L, Nucera V, Barilaro G, Masala IF, Talotta R, Caso P, Scarpa R, Sarzi-Puttini P, Atzeni F (2018) From autoinflammation to autoimmunity: old and recent findings. Clin Rheumatol 37:2305–2321CrossRefPubMed
26.
Zurück zum Zitat Scrivo R, Vasile M, Bartosiewicz I, Valesini G (2011) Inflammation as “common soil” of the multifactorial diseases. Autoimmun Rev 10:369–374CrossRefPubMed Scrivo R, Vasile M, Bartosiewicz I, Valesini G (2011) Inflammation as “common soil” of the multifactorial diseases. Autoimmun Rev 10:369–374CrossRefPubMed
27.
Zurück zum Zitat Dutheil F, Gordon BA, Naughton G, Crendal E, Courteix D, Chaplais E, Thivel D, Lac G, Benson AC (2018) Cardiovascular risk of adipokines: a review. J Int Med Res 46:2082–2095CrossRefPubMed Dutheil F, Gordon BA, Naughton G, Crendal E, Courteix D, Chaplais E, Thivel D, Lac G, Benson AC (2018) Cardiovascular risk of adipokines: a review. J Int Med Res 46:2082–2095CrossRefPubMed
28.
Zurück zum Zitat Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A, Monfrecola G, Balato N, Ayala F, Romanelli M, Balato A (2016) Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol 12:1299–1308CrossRefPubMed Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A, Monfrecola G, Balato N, Ayala F, Romanelli M, Balato A (2016) Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol 12:1299–1308CrossRefPubMed
29.
Zurück zum Zitat Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72:1956–1961CrossRefPubMed Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72:1956–1961CrossRefPubMed
30.
Zurück zum Zitat Feld J, Nissan S, Eder L, Rahat MA, Elias M, Rimar D, Laor A, Bitterman H, Zisman D (2018) Increased prevalence of metabolic syndrome and adipocytokine levels in a psoriatic arthritis cohort. J Clin Rheumatol 24:302–307CrossRefPubMed Feld J, Nissan S, Eder L, Rahat MA, Elias M, Rimar D, Laor A, Bitterman H, Zisman D (2018) Increased prevalence of metabolic syndrome and adipocytokine levels in a psoriatic arthritis cohort. J Clin Rheumatol 24:302–307CrossRefPubMed
31.
Zurück zum Zitat Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG (2017) Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology 233:378–389CrossRefPubMed Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG (2017) Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology 233:378–389CrossRefPubMed
32.
Zurück zum Zitat Vachatova S, Andrys C, Krejsek J, Salavec M, Ettler K, Rehacek V, Cermakova E, Malkova A, Fiala Z, Borska L (2016) Metabolic syndrome and selective inflammatory markers in psoriatic patients. J Immunol Res 2016:5380792CrossRefPubMedPubMedCentral Vachatova S, Andrys C, Krejsek J, Salavec M, Ettler K, Rehacek V, Cermakova E, Malkova A, Fiala Z, Borska L (2016) Metabolic syndrome and selective inflammatory markers in psoriatic patients. J Immunol Res 2016:5380792CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Wolk K, Sabat R (2016) Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord 17:305–317CrossRefPubMed Wolk K, Sabat R (2016) Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord 17:305–317CrossRefPubMed
34.
Zurück zum Zitat Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939CrossRefPubMed Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939CrossRefPubMed
35.
Zurück zum Zitat Dikbas O, Tosun M, Bes C, Tonuk SB, Aksehirli OY, Soy M (2016) Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis 19:672–677CrossRefPubMed Dikbas O, Tosun M, Bes C, Tonuk SB, Aksehirli OY, Soy M (2016) Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis 19:672–677CrossRefPubMed
36.
Zurück zum Zitat Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG (2018) Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. Br J Dermatol 179:273–281PubMed Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG (2018) Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. Br J Dermatol 179:273–281PubMed
37.
Zurück zum Zitat Mattu HS, Randeva HS (2013) Role of adipokines in cardiovascular disease. J Endocrinol 216:T17–T36CrossRefPubMed Mattu HS, Randeva HS (2013) Role of adipokines in cardiovascular disease. J Endocrinol 216:T17–T36CrossRefPubMed
38.
Zurück zum Zitat Makris MC, Alexandrou A, Papatsoutsos EG, Malietzis G, Tsilimigras DI, Guerron AD, Moris D (2017) Ghrelin and obesity: identifying gaps and dispelling myths. A reappraisal. In Vivo 31:1047–1050PubMedPubMedCentral Makris MC, Alexandrou A, Papatsoutsos EG, Malietzis G, Tsilimigras DI, Guerron AD, Moris D (2017) Ghrelin and obesity: identifying gaps and dispelling myths. A reappraisal. In Vivo 31:1047–1050PubMedPubMedCentral
39.
Zurück zum Zitat Baatar D, Patel K, Taub DD (2011) The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 340:44–58CrossRefPubMed Baatar D, Patel K, Taub DD (2011) The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 340:44–58CrossRefPubMed
40.
Zurück zum Zitat Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW Jr, Taub DD (2004) Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114:57–66CrossRefPubMedPubMedCentral Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW Jr, Taub DD (2004) Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114:57–66CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Ozdemir M, Yüksel M, Gökbel H, Okudan N, Mevlitoğlu I (2012) Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol 39:443–448CrossRefPubMed Ozdemir M, Yüksel M, Gökbel H, Okudan N, Mevlitoğlu I (2012) Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol 39:443–448CrossRefPubMed
42.
Zurück zum Zitat Ucak H, Demir B, Cicek D, Erden I, Aydin S, Dertlioglu SB, Arica M (2014) Metabolic changes and serum ghrelin level in patients with psoriasis. Dermatol Res Pract 2014:175693CrossRefPubMedPubMedCentral Ucak H, Demir B, Cicek D, Erden I, Aydin S, Dertlioglu SB, Arica M (2014) Metabolic changes and serum ghrelin level in patients with psoriasis. Dermatol Res Pract 2014:175693CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Caso F, Del Puente A, Oliviero F, Peluso R, Girolimetto N, Bottiglieri P, Foglia F, Benigno C, Tasso M, Punzi L, Scarpa R, Costa L (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol 37:579–586CrossRefPubMed Caso F, Del Puente A, Oliviero F, Peluso R, Girolimetto N, Bottiglieri P, Foglia F, Benigno C, Tasso M, Punzi L, Scarpa R, Costa L (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol 37:579–586CrossRefPubMed
44.
45.
Zurück zum Zitat Carniglia L, Ramírez D, Durand D, Saba J, Turati J, Caruso C, Scimonelli TN, Lasaga M (2017) Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases. Mediat Inflamm 2017:5048616CrossRef Carniglia L, Ramírez D, Durand D, Saba J, Turati J, Caruso C, Scimonelli TN, Lasaga M (2017) Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases. Mediat Inflamm 2017:5048616CrossRef
46.
Zurück zum Zitat Lim G, Wang S, Zhang Y, Tian Y, Mao J (2009) Spinal leptin contributes to the pathogenesis of neuropathic pain in rodents. J Clin Invest 119:295–304PubMedPubMedCentral Lim G, Wang S, Zhang Y, Tian Y, Mao J (2009) Spinal leptin contributes to the pathogenesis of neuropathic pain in rodents. J Clin Invest 119:295–304PubMedPubMedCentral
47.
Zurück zum Zitat Tian Y, Wang S, Ma Y, Lim G, Kim H, Mao J (2011) Leptin enhances NMDA-induced spinal excitation in rats: a functional link between adipocytokine and neuropathic pain. Pain 152:1263–1271CrossRefPubMedPubMedCentral Tian Y, Wang S, Ma Y, Lim G, Kim H, Mao J (2011) Leptin enhances NMDA-induced spinal excitation in rats: a functional link between adipocytokine and neuropathic pain. Pain 152:1263–1271CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Hu F, Cui Y, Guo R, Chen J, Guo R, Shen N, Hua X, Mo L, Feng J (2014) Spinal leptin contributes to the development of morphine antinociceptive tolerance by activating the STAT3-NMDA receptor pathway in rats. Mol Med Rep 10:923–930CrossRefPubMed Hu F, Cui Y, Guo R, Chen J, Guo R, Shen N, Hua X, Mo L, Feng J (2014) Spinal leptin contributes to the development of morphine antinociceptive tolerance by activating the STAT3-NMDA receptor pathway in rats. Mol Med Rep 10:923–930CrossRefPubMed
49.
Zurück zum Zitat Fatel ECS, Rosa FT, Simão ANC, Dichi I (2018) Adipokines in rheumatoid arthritis. Adv Rheumatol 58:25CrossRefPubMed Fatel ECS, Rosa FT, Simão ANC, Dichi I (2018) Adipokines in rheumatoid arthritis. Adv Rheumatol 58:25CrossRefPubMed
50.
Zurück zum Zitat Dervišević A, Resić H, Sokolović Š, Babić N, Avdagić N, Začiragić A, Bečiragić A, Fajkić A, Lepara O, Hadžović-Dzuvo A (2018) Leptin is associated with disease activity but not with anthropometric indices in rheumatoid arthritis patients. Arch Med Sci 14:1080–1086CrossRefPubMed Dervišević A, Resić H, Sokolović Š, Babić N, Avdagić N, Začiragić A, Bečiragić A, Fajkić A, Lepara O, Hadžović-Dzuvo A (2018) Leptin is associated with disease activity but not with anthropometric indices in rheumatoid arthritis patients. Arch Med Sci 14:1080–1086CrossRefPubMed
51.
Zurück zum Zitat Bustos Rivera-Bahena C, Xibillé-Friedmann DX, González-Christen J, Carrillo-Vázquez SM, Montiel-Hernández JL (2016) Peripheral blood leptin and resistin levels as clinical activity biomarkers in Mexican rheumatoid arthritis patients. Reumatol Clin 12:323–326CrossRefPubMed Bustos Rivera-Bahena C, Xibillé-Friedmann DX, González-Christen J, Carrillo-Vázquez SM, Montiel-Hernández JL (2016) Peripheral blood leptin and resistin levels as clinical activity biomarkers in Mexican rheumatoid arthritis patients. Reumatol Clin 12:323–326CrossRefPubMed
52.
Zurück zum Zitat Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, Andersone D, Bergman M, Craig-Muller J, Detert J, Georgescu L, Gossec L, Hamoud H, Jacobs JW, Laurindo IM, Majdan M, Naranjo A, Pandya S, Pohl C, Schett G, Selim ZI, Toloza S, Yamanaka H, Sokka T (2012) Determinants of discordance in patients’ and physicians’ rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 64:206–214CrossRef Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, Andersone D, Bergman M, Craig-Muller J, Detert J, Georgescu L, Gossec L, Hamoud H, Jacobs JW, Laurindo IM, Majdan M, Naranjo A, Pandya S, Pohl C, Schett G, Selim ZI, Toloza S, Yamanaka H, Sokka T (2012) Determinants of discordance in patients’ and physicians’ rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 64:206–214CrossRef
53.
Zurück zum Zitat Fassio A, Gatti D, Gisondi P, Girolomoni G, Viapiana O, Giollo A, Zamboni M, Rossini M, Idolazzi L (2017) Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo 69:105–110CrossRefPubMed Fassio A, Gatti D, Gisondi P, Girolomoni G, Viapiana O, Giollo A, Zamboni M, Rossini M, Idolazzi L (2017) Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo 69:105–110CrossRefPubMed
Metadaten
Titel
Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset “sine psoriasis”
verfasst von
Francesco Caso
Loredana Postiglione
Bianca Covelli
Margherita Ricciardone
Gaetano Di Spigna
Pietro Formisano
Vittoria D’Esposito
Nicolò Girolimetto
Marco Tasso
Rosario Peluso
Luca Navarini
Massimo Ciccozzi
Domenico Paolo Emanuele Margiotta
Francesca Oliviero
Antonella Afeltra
Leonardo Punzi
Antonio Del Puente
Raffaele Scarpa
Luisa Costa
Publikationsdatum
30.05.2019
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 9/2019
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04619-w

Weitere Artikel der Ausgabe 9/2019

Clinical Rheumatology 9/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.